Effects of Zeng Sheng Ping/ACAPHA on malignant brain tumor growth and notch signaling

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2689-2696

  Lim, Kah Jing ^a   Rajan, Kda ^a   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACAPHA; Antitumor B; DAOY medulloblastoma cells; Glioblastoma; Medulloblastoma; Notch; U87 glioblastoma cells; Zeng Sheng Ping

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CHINESE DRUG; NESTIN; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; ZENG SHENG PING;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHINESE MEDICINE; DRUG EFFECT; GLIOMA; GLIOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUGS, CHINESE HERBAL; FEMALE; GLIOBLASTOMA; HUMANS; MEDULLOBLASTOMA; MICE; MICE, NUDE; PHYTOTHERAPY; RANDOM ALLOCATION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865692578     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: IARC, 2007.
2. Fan X: Inhibitory effect of antitumor-B and retinamide on precancerous lesions of the bladder in rats. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 15(1): 71-73, 1993 (in Chinese).
3. Sun Z, Guan X, Li N, Liu X and Chen X: Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with Zeng Sheng Ping, a mixture of medicinal herbs. Oral Oncol 46(2): 105-110, 2010.
4. Wang J: Results of phase III clinical trial of zeng sheng-ping in the treatment of patients with esophageal epithelial hyperplasia. Zhonghua Zhong Liu Za Zhi 22 (6): 510-512, 2000 (in Chinese).
5. Lin P, Zhang J, Rong Z, Han R, Xu S, Gao R, Ding Z, Wang J, Feng H and Cao S: Studies on medicamentous inhibitory therapy for esophageal precancerous lesions - 3- and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. Proc Chin Acad Med Sci Peking Union Med Coll 5(3): 121-129, 1990.
6. Ding Z, Gao F and Lin P: Long-term effect of treating patients with precancerous lesions of the esophagus. Zhonghua Zhong Liu Za Zhi 21(4): 275-277, 1999 (in Chinese).
7. Hou J, Lin PZ, Chen ZF, Ding ZW, Li SS, Men FS, Guo LP, He YT, Qiao CY, Guo CL, Duan JP and Wen DG: Field population-based blocking treatment of esophageal epithelia dysplasia. World J Gastroenterol 8(3): 418-422, 2002.
8. Zhang Z, Wang Y, Yao R, Li J, Yan Y, La Regina M, Lemon WL, Grubbs CJ, Lubet RA and You M: Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene 23(21): 3841-3850, 2004.
9. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A and Holland E: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4(11): e7752, 2009.
10. Chen J, Kesari S, Rooney C, Strack PR, Shen H, Wu L and Griffin JD: Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 1(8): 822-835, 2010.
11. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L and Pieper RO: Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 106(3): 417-427, 2007.
12. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG and Fine HA: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65(6): 2353-2363, 2005.
13. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, Zhou P, Yin DD, Zheng QJ, Liang L, Zhang SZ, Feng L, Yao LB, Yang AG, Han H and Chen JY: Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem 307(1- 2): 101-108, 2008.
14. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL and Eberhart CG: NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28(1): 5-16, 2010.
15. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM and Eberhart CG: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66(15): 7445-7452, 2006.
16. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA and Parker EM: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279(13): 12876-12882, 2004.
17. Gao G and Law FC: Physiologically based pharmacokinetics of matrine in the rat after oral administration of pure chemical and ACAPHA. Drug Metab Dispos 37(4): 884-891, 2009.
18. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N and Eberhart CG: The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res 16(24): 6060-6070, 2010.
19. Bar EE, Lin A, Mahairaki V, Matsui W and Eberhart CG: Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177(3): 1491-1502, 2010.
20. Boehm T, Folkman J, Browder T and O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658): 404-407, 1997.
21. Lin P, Chen Z, Hou J, Liu T and Wang J: Chemoprevention of esophageal cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 20(6): 413-418, 1998 (in Chinese).
22. Laywell ED, Kukekov VG and Steindler DA: Multipotent neurospheres can be derived from forebrain subependymal zone and spinal cord of adult mice after protracted postmortem intervals. Exp Neurol 156(2): 430-433, 1999.
23. Kornblum HI, Yanni DS, Easterday MC and Seroogy KB: Expression of the EGF receptor family members ErbB2, ErbB3, and ErbB4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. Dev Neurosci 22(1-2): 16-24, 2000.
24. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK and Fine HA: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5): 391-403, 2006.
25. Sanchez-Martin M: Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr Stem Cell Res Ther 3(3): 197-207, 2008.
26. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi A: Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19): 7011-7021, 2004.
27. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414(6859): 105-111, 2001.
28. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5(4): 275-284, 2005.
29. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A and Eberhart CG: Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64(21): 7787-7793, 2004.
30. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MC, Zweifel C, Tolnay M, Wasner M, Mergenthaler S, Miserez AR, Kiss R, Lino MM, Merlo A, Chiquet-Ehrismann R and Boulay JL: Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res 69(2): 458-465, 2009.
31. Nickoloff BJ, Osborne BA and Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22(42): 6598-6608, 2003.
32. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN and Sullenger BA: Notch promotes radioresistance of glioma stem cells. Stem Cells 28(1): 17-28, 2010.
33. Farnie G and Clarke RB: Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 3(2): 169-175, 2007.
34. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, Santini D, Ceccarelli C, Chieco P and Bonafe M: p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 25(3): 807-815, 2007.
35. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B and Miele L: Targeting Notch to target cancer stem cells. Clin Cancer Res 16(12): 3141-3152, 2010.